Current peptide vaccine and immunotherapy approaches against Alzheimer’s disease

Parrocha, Chelsea Marie T.; Nowick, James S.

doi:10.1002/pep2.24289

Cited by 24Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchNeuroinflammation and Neurodegeneration Mechanisms

Current peptide vaccine and immunotherapy approaches against Alzheimer’s disease

Open access

Parrocha, Chelsea Marie T., Nowick, James S.·2023·Peptide Science

DOI 10.1002/pep2.24289PMC PMC9916509

Open this paper in CoChat — free account Open PDF

Abstract

Peptide vaccines and immunotherapies against aggregating proteins involved in the pathogenesis and progression of Alzheimer's disease (AD) - the β-amyloid peptide (Aβ) and tau - are promising therapeutic avenues against AD. Two decades of effort has led to the controversial FDA approval of the monoclonal antibody Aducanumab (Aduhelm), which has subsequentially sparked the revival and expedited review of promising monoclonal antibody immunotherapies that target Aβ. In this review, we explore the development of Aβ and tau peptide vaccines and immunotherapies with monoclonal antibodies in clinical trials against AD.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1002/pep2.24289

Cites

66 of 66 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

CAD106 is an active Aβ immunotherapy currently undergoing clinical development, involving multiple doses of whole Aβ1-6 peptide linked to ADP-Q carrier, a virus-like particle that generates high-titer anti-Aβ antibodies.
“CAD106, a further active Aβ immunotherapy, is presently undergoing clinical development. It involves administering multiple doses of the whole Aβ1–6 peptide linked to the ADP-Q carrier, a virus-like particle that generates high-titer anti-Aβ antibodies [140,141,153,154].”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [141]
AN-1792 was withdrawn during Phase II of the trial due to side effects associated with meningoencephalitis, reported in 6% of patients.
“However, AN-1792 was withdrawn during Phase II of the trial due to side effects associated with meningoencephalitis, which were reported in 6% of patients [140,141,142,143,144].”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [141]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Development of Virus-Like Particle Technology from Small Highly Symmetric to Large Complex Virus-Like Particle Structures
Pushko, P., Pumpens, P., & Grens, E. (2013) · Intervirology · doi:10.1159/000346773 · Cited by 5,970 · see citing works
Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160 · see citing works
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059 · see citing works
2021 Alzheimer's disease facts and figures
Anonymous (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12328 · Cited by 2,236 · see citing works
Alzheimer's disease
Masters, C. L., Bateman, R., Blennow, K., Rowe, C. C., Sperling, R. A., & Cummings, J. L. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.56 · Cited by 1,853 · see citing works
Donanemab in Early Alzheimer’s Disease
Mintun, M. A., Lo, A. C., Duggan Evans, C., Wessels, A. M., Ardayfio, P. A., Andersen, S. W., Shcherbinin, S., Sparks, J., Sims, J. R., Brys, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2100708 · Cited by 1,728 · see citing works
Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies
Yamazaki, Y., Zhao, N., Caulfield, T. R., Liu, C.-C., & Bu, G. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0228-7 · Cited by 1,425 · see citing works
The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Aβ protofibril formation
Nilsberth, C., Westlind-Danielsson, A., Eckman, C. B., Condron, M. M., Axelman, K., Forsell, C., Stenh, C., Luthman, J., Teplow, D. B., Younkin, S. G., et al. (2001) · Nature Neuroscience · doi:10.1038/nn0901-887 · Cited by 1,209 · see citing works
Tau-targeting therapies for Alzheimer disease
Congdon, E. E., & Sigurdsson, E. M. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0013-z · Cited by 1,113 · see citing works
A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody
Swanson, C. J., Zhang, Y., Dhadda, S., Wang, J., Kaplow, J., Lai, R. Y. K., Lannfelt, L., Bradley, H., Rabe, M., Koyama, A., et al. (2021) · Alzheimer's Research & Therapy · doi:10.1186/s13195-021-00813-8 · Cited by 847 · see citing works
Clinical trials of new drugs for Alzheimer disease
Huang, L.-K., Chao, S.-P., & Hu, C.-J. (2020) · Journal of Biomedical Science · doi:10.1186/s12929-019-0609-7 · Cited by 702 · see citing works
A mouse model for SARS-CoV-2-induced acute respiratory distress syndrome
Hong, W., Yang, H. J., Bi, Z., He, C., Hong, L., Yu, W., Yang, Y., Fan, C., Lu, S., Peng, X., et al. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00451-w · Cited by 631 · see citing works
Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients with Early Alzheimer Disease
Salloway, S., Chalkias, S., Barkhof, F., Burkett, P., Barakos, J., Purcell, D., Suhy, J., Forrestal, F., Tian, Y., Umans, K., et al. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2021.4161 · Cited by 619 · see citing works
Treatment Combinations for Alzheimer’s Disease: Current and Future Pharmacotherapy Options
Cummings, J. L., Tong, G., & Ballard, C. (2019) · Journal of Alzheimer's Disease · doi:10.3233/jad-180766 · Cited by 588 · see citing works
Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019
Knopman, D. S., Jones, D. T., & Greicius, M. D. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12213 · Cited by 524 · see citing works
Immunotherapy Targeting Pathological Tau Conformers in a Tangle Mouse Model Reduces Brain Pathology with Associated Functional Improvements
Asuni, A. A., Boutajangout, A., Quartermain, D., & Sigurdsson, E. M. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.2361-07.2007 · Cited by 506 · see citing works
Gantenerumab: A Novel Human Anti-Aβ Antibody Demonstrates Sustained Cerebral Amyloid-β Binding and Elicits Cell-Mediated Removal of Human Amyloid-β
Bohrmann, B., Baumann, K., Benz, J., Gerber, F., Huber, W., Knoflach, F., Messer, J., Oroszlan, K., Rauchenberger, R., Richter, W. F., et al. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-110977 · Cited by 448 · see citing works
A Plaque-Specific Antibody Clears Existing β-amyloid Plaques in Alzheimer's Disease Mice
DeMattos, R. B., Lu, J., Tang, Y., Racke, M. M., DeLong, C. A., Tzaferis, J. A., Hole, J. T., Forster, B. M., McDonnell, P. C., Liu, F., et al. (2012) · Neuron · doi:10.1016/j.neuron.2012.10.029 · Cited by 442 · see citing works
Brain delivery of therapeutic proteins using an Fc fragment blood-brain barrier transport vehicle in mice and monkeys
Kariolis, M. S., Wells, R. C., Getz, J. A., Kwan, W., Mahon, C. S., Tong, R. K., Kim, D. J., Srivastava, A., Bédard, C., Henne, K. R., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay1359 · Cited by 355 · see citing works
An Effector-Reduced Anti- -Amyloid (A ) Antibody with Unique A Binding Properties Promotes Neuroprotection and Glial Engulfment of A
Adolfsson, O., Pihlgren, M., Toni, N., Varisco, Y., Buccarello, A. L., Antoniello, K., Lohmann, S., Piorkowska, K., Gafner, V., Atwal, J. K., et al. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.4742-11.2012 · Cited by 317 · see citing works
Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial
Novák, P., Schmidt, R., Kontseková, E., Žilka, N., Kováčech, B., Škrabana, R., Kazmerova, Z., Katina, S., Fialová, Ľ., Prčina, M., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30331-3 · Cited by 306 · see citing works
The Murine Version of BAN2401 (mAb158) Selectively Reduces Amyloid-β Protofibrils in Brain and Cerebrospinal Fluid of tg-ArcSwe Mice
Tucker, S., Möller, C., Tegerstedt, K., Lord, A., Laudon, H., Sjödahl, J., Söderberg, L., Spens, E., Sahlin, C., Waara, E. R., et al. (2015) · Journal of Alzheimer’s Disease · doi:10.3233/jad-140741 · Cited by 272 · see citing works
Efficacy and Safety of A Liposome-Based Vaccine against Protein Tau, Assessed in Tau.P301L Mice That Model Tauopathy
Theunis, C., Crespo-Biel, N., Gafner, V., Pihlgren, M., López-Deber, M. P., Reis, P., Hickman, D. T., Adolfsson, O., Chuard, N., Ndao, D. M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072301 · Cited by 259 · see citing works
First-in-man tau vaccine targeting structural determinants essential for pathological tau–tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer’s disease model
Kontseková, E., Žilka, N., Kováčech, B., Novák, P., & Novák, M. (2014) · Alzheimer s Research & Therapy · doi:10.1186/alzrt278 · Cited by 248 · see citing works
Aβ(1-42) tetramer and octamer structures reveal edge conductivity pores as a mechanism for membrane damage
Ciudad, S., Puig, E., Botzanowski, T., Meigooni, M., Arango, A. S., Do, J., Mayzel, M., Bayoumi, M., Chaignepain, S., Maglia, G., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16566-1 · Cited by 228 · see citing works
Persistent neuropathological effects 14 years following amyloid-β immunization in Alzheimer’s disease
Nicoll, J. A. R., Buckland, G. R., Harrison, C. H., Page, A. M., Harris, S., Love, S., Neal, J., Holmes, C., & Boche, D. (2019) · Brain · doi:10.1093/brain/awz142 · Cited by 205 · see citing works
The Second-Generation Active A Immunotherapy CAD106 Reduces Amyloid Accumulation in APP Transgenic Mice While Minimizing Potential Side Effects
Wießner, C., Wiederhold, K., Tissot, A. C., Frey, P., Danner, S., Jacobson, L. H., Jennings, G. T., Lüönd, R. M., Ortmann, R., Reichwald, J., et al. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.0293-11.2011 · Cited by 190 · see citing works
ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer’s disease
Novak, P., Kovacech, B., Katina, S., Schmidt, R., Scheltens, P., Kontsekova, E., Ropele, S., Fialova, L., Kramberger, M., Paulenka-Ivanovova, N., et al. (2021) · Nature Aging · doi:10.1038/s43587-021-00070-2 · Cited by 187 · see citing works
APOE immunotherapy reduces cerebral amyloid angiopathy and amyloid plaques while improving cerebrovascular function
Xiong, M., Jiang, H., Serrano, J. R., Gonzales, E. R., Wang, C., Gratuze, M., Hoyle, R., Bien-Ly, N., Silverman, A. P., Sullivan, P. M., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abd7522 · Cited by 179 · see citing works
Targeting of nonlipidated, aggregated apoE with antibodies inhibits amyloid accumulation
Liao, F., Li, A., Xiong, M., Bien-Ly, N., Jiang, H., Zhang, Y., Finn, M. B., Hoyle, R., Keyser, J., Lefton, K. B., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96429 · Cited by 178 · see citing works
Liposomal vaccines with conformation-specific amyloid peptide antigens define immune response and efficacy in APP transgenic mice
Muhs, A., Hickman, D. T., Pihlgren, M., Chuard, N., Giriens, V., Meerschman, C., der Auwera, I. V., LEUVEN, F. V., Sugawara, M., Weingertner, M.-C., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0703137104 · Cited by 176 · see citing works
Passive immunotherapies targeting Aβ and tau in Alzheimer's disease
Plotkin, S. S., & Cashman, N. R. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105010 · Cited by 156 · see citing works
UB‐311, a novel UBITh <sup>®</sup> amyloid β peptide vaccine for mild Alzheimer's disease
Wang, C. Y., Wang, P., Chiu, M., Finstad, C. L., Lin, F., Lynn, S., Tai, Y., De Fang, X., Zhao, K., Hung, C., et al. (2017) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2017.03.005 · Cited by 150 · see citing works
Active Aβ immunotherapy CAD106 in Alzheimer's disease: A phase 2b study
Vandenberghe, R. R., Riviere, M., Caputo, A., Sóvágó, J., Maguire, R. P., Farlow, M. R., Marotta, G., Sánchez‐Valle, R., Scheltens, P., Ryan, J. M., et al. (2016) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2016.12.003 · Cited by 141 · see citing works
Pre-clinical characterisation of E2814, a high-affinity antibody targeting the microtubule-binding repeat domain of tau for passive immunotherapy in Alzheimer’s disease
Roberts, M., Sevastou, I., Imaizumi, Y., Mistry, K., Talma, S., Dey, M., Gartlon, J., Ochiai, H., Zhou, Z., Akasofu, S., et al. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-0884-2 · Cited by 135 · see citing works
Epitope determines efficacy of therapeutic anti-Tau antibodies in a functional assay with human Alzheimer Tau
Courade, J., Angers, R. C., Mairet‐Coello, G., Pacico, N., Tyson, K. L., Lightwood, D. J., Munro, R., McMillan, D., Griffin, R., BAKER, T. S., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1911-2 · Cited by 131 · see citing works
AADvac1, an Active Immunotherapy for Alzheimer's Disease and Non Alzheimer Tauopathies: An Overview of Preclinical and Clinical Development
Novák, P., Žilka, N., Žilková, M., Kováčech, B., Škrabana, R., Ondrus, M., Fialová, L., Kontseková, E., Otto, M., & Novák, M. (2019) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2018.45 · Cited by 115 · see citing works
Identification of structural determinants on tau protein essential for its pathological function: novel therapeutic target for tau immunotherapy in Alzheimer’s disease
Kontsekova, E., Zilka, N., Kovacech, B., Skrabana, R., & Novak, M. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt277 · Cited by 112 · see citing works
Safety, tolerability and immunogenicity of an active anti-Aβ40 vaccine (ABvac40) in patients with Alzheimer’s disease: a randomised, double-blind, placebo-controlled, phase I trial
Lacosta, A.-M., Pascual-Lucas, M., Pesini, P., Casabona, D., Pérez-Grijalba, V., Marcos-Campos, I., Sarasa, L., Canudas, J., Badi, H., Monleón, I., et al. (2018) · Alzheimer's Research & Therapy · doi:10.1186/s13195-018-0340-8 · Cited by 111 · see citing works
Elucidating the Structures of Amyloid Oligomers with Macrocyclic β-Hairpin Peptides: Insights into Alzheimer’s Disease and Other Amyloid Diseases
Kreutzer, A. G., & Nowick, J. S. (2018) · Accounts of Chemical Research · doi:10.1021/acs.accounts.7b00554 · Cited by 108 · see citing works
Self-citation
Antibody semorinemab reduces tau pathology in a transgenic mouse model and engages tau in patients with Alzheimer’s disease
Ayalon, G., Lee, S.-H., Adolfsson, O., Foo‐Atkins, C., Atwal, J. K., Blendstrup, M., Booler, H. S., Bravo, J., Brendza, R. P., Brunstein, F., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abb2639 · Cited by 108 · see citing works
Advances and considerations in AD tau-targeted immunotherapy
Bittar, A., Bhatt, N. N., & Kayed, R. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104707 · Cited by 105 · see citing works
Pyroglutamate Aβ cascade as drug target in Alzheimer’s disease
Bayer, T. A. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01409-2 · Cited by 98 · see citing works
Current Status of Clinical Trials on Tau Immunotherapies
Ji, C., & Sigurdsson, E. M. (2021) · Drugs · doi:10.1007/s40265-021-01546-6 · Cited by 96 · see citing works
Sequence-independent Control of Peptide Conformation in Liposomal Vaccines for Targeting Protein Misfolding Diseases
Hickman, D. T., López-Deber, M. P., Ndao, D. M., Silva, A. B., Nand, D., Pihlgren, M., Giriens, V., Madani, R., St-Pierre, A., Karastaneva, H., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.186338 · Cited by 83 · see citing works
Vaccination against β-Amyloid as a Strategy for the Prevention of Alzheimer’s Disease
Mantile, F., & Prisco, A. (2020) · Biology · doi:10.3390/biology9120425 · Cited by 56 · see citing works
Antibody Therapeutics Targeting Aβ and TauPreprint
Gallardo, G., & Holtzman, D. M. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a024331 · Cited by 51 · see citing works
Alzheimer's and Aducanumab: Unjust Profits and False Hopes
Fleck, L. M. (2021) · The Hastings Center Report · doi:10.1002/hast.1264 · Cited by 50 · see citing works
Prophylactic Active Tau Immunization Leads to Sustained Reduction in Both Tau and Amyloid-β Pathologies in 3xTg Mice
Rajamohamedsait, H., Rasool, S., Rajamohamedsait, W., Lin, Y., & Sigurdsson, E. M. (2017) · Scientific Reports · doi:10.1038/s41598-017-17313-1 · Cited by 49 · see citing works
A retrospective analysis of the Alzheimer's disease vaccine progress – The critical need for new development strategies
Marciani, D. J. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13608 · Cited by 48 · see citing works
The Problem of Aducanumab for the Treatment of Alzheimer Disease
Alexander, G. C., & Karlawish, J. (2021) · Annals of Internal Medicine · doi:10.7326/m21-2603 · Cited by 47 · see citing works
Alzheimer’s Disease: Drug Discovery
Huang, X. (2020) · Exon Publications eBooks · doi:10.36255/exonpublications.alzheimersdisease.2020 · Cited by 45 · see citing works
Phase 1 Studies of the Anti-Tau Monoclonal Antibody JNJ-63733657 in Healthy Participants and Participants with Alzheimer's Disease
Galpern, W. R., Triana‐Baltzer, G., Li, L., Kolen, K. V., Timmers, M., Haeverans, K., Janssens, L., Kolb, H. C., Nandy, P., Aida, K., et al. (2024) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2024.163 · Cited by 38 · see citing works
Exploring amyloid oligomers with peptide model systems
Samdin, T. D., Kreutzer, A. G., & Nowick, J. S. (2021) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2021.05.004 · Cited by 35 · see citing works
Self-citation
P1‐052: A SINGLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF THE ANTI‐PHOSPHO‐TAU ANTIBODY JNJ‐63733657 IN HEALTHY SUBJECTS
Galpern, W. R., Mercken, M. H., Kolen, K. V., Timmers, M., Katrin, H., Janssens, L., Triana‐Baltzer, G., Kolb, H. C., Jacobs, T., Nandy, P., et al. (2019) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2019.06.077 · Cited by 29 · see citing works
Discovery of a novel pseudo β-hairpin structure of N-truncated amyloid-β for use as a vaccine against Alzheimer’s disease
Bakrania, P., Hall, G., Bouter, Y., Bouter, C., Beindorff, N., Cowan, R. H., Davies, S. L., Price, J., Mpamhanga, C., Love, E. A., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01385-7 · Cited by 29 · see citing works
Site-specific peptide vaccines for immunotherapy and immunization against chronic diseases, cancer, infectious diseases, and for veterinary applications
Wang, C. C., & Walfield, A. M. (2005) · Vaccine · doi:10.1016/j.vaccine.2005.01.007 · Cited by 26 · see citing works
Peptide-Based Vaccines for Neurodegenerative Diseases: Recent Endeavors and Future Perspectives
Vassilakopoulou, V., Karachaliou, C., Evangelou, A., Zikos, C. C., & Livaniou, E. (2021) · Vaccines · doi:10.3390/vaccines9111278 · Cited by 26 · see citing works
An amyloid beta vaccine that safely drives immunity to a key pathological species in Alzheimer’s disease: pyroglutamate amyloid beta
Vukicevic, M., Fiorini, E., Siegert, S., Carpintero, R., Rincón-Restrepo, M., López-Deber, M. P., Piot, N., Ayer, M., Rentero, I., Babolin, C., et al. (2022) · Brain Communications · doi:10.1093/braincomms/fcac022 · Cited by 25 · see citing works
Recent advances in tau-directed immunotherapy against Alzheimer’s disease: an overview of pre-clinical and clinical development
Ng, P. Y., Chang, I. S., Koh, R. Y., & Chye, S. M. (2020) · Metabolic Brain Disease · doi:10.1007/s11011-020-00591-6 · Cited by 24 · see citing works
Norovirus P particle-based tau vaccine-generated phosphorylated tau antibodies markedly ameliorate tau pathology and improve behavioral deficits in mouse model of Alzheimer’s disease
Sun, Y., Guo, Y., Feng, X., Fu, L., Zheng, Y., Dong, Y., Zhang, Y., Yu, X., Kong, W., & Wu, H. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00416-z · Cited by 14 · see citing works
Targeting Alzheimer’s Disease at the Right Time and the Right Place: Validation of a Personalized Approach to Diagnosis and Treatment
Gauthier, S. G., Ng, K. P., Pascoal, T. A., Zhang, H., & Rosa‐Neto, P. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-179924 · Cited by 13 · see citing works
Phos-tau peptide immunization of amyloid-tg-mice reduced non-mutant phos-tau pathology, improved cognition and reduced amyloid plaques
Benhamron, S., Rozenstein‐Tsalkovich, L., Nitzan, K., Abramsky, O., & Rosenmann, H. (2018) · Experimental Neurology · doi:10.1016/j.expneurol.2018.02.004 · Cited by 11 · see citing works
FDA's green light, science's red light
Perlmutter, J. S. (2021) · Science · doi:10.1126/science.abk0575 · Cited by 7 · see citing works
Design of the phase II clinical study of the tau vaccine AADvac1 in patients with mild Alzheimer’s disease
Ondrus, M., & Novák, P. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.01.115 · Cited by 6 · see citing works
Correction to: Norovirus P particle-based tau vaccine-generated phosphorylated tau antibodies markedly ameliorate tau pathology and improve behavioral deficits in mouse model of Alzheimer’s disease
Sun, Y., Guo, Y., Feng, X., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00657-6 · Cited by 6 · see citing works

Flagged first, then by citations

Research works printed but not linked: 8

[9]C. Wiessner, K.‐H. Wiederhold, A. C. Tissot, P. Frey, S. Danner, L. H. Jacobson, G. T. Jennings, R. Lüönd, R. Ortmann, J. Reichwald, M. Zurini, A. Mir, M. F. Bachmann, M. Staufenbiel, J. Neurosci. 2011, 31, 9323. 21697382 PMC6623465
[29]Active Tau Vaccine: Hints of Slowing Neurodegeneration, https://www.alzforum.org/news/conference-coverage/active-tau-vaccine-hints-slowing-neurodegeneration (accessed: February 2022).
[39]M. Ondrus, P. Novak, Neurobiol. Aging 2016, 39, S26.
[47]J. S. Perlmutter, Science 2021, 372, 1371.
[92]Alzforum, https://www.alzforum.org/news/conference-coverage/n-terminal-tau-antibodies-fade-mid-domain-ones-push-fore (accessed: February 2022).
[99]An Open‐Label Phase 1b/2 Study to Assess Safety and Target Engagement of E2814 in Subjects With Mild to Moderate Cognitive Impairment Due to Dominantly Inherited Alzheimer's Disease; Clinical trial registration NCT04971733; clinicaltrials.gov, 2021. PMC13088717 41964075
[107]Alzforum, https://www.alzforum.org/news/conference-coverage/shuttle-unloads-more-gantenerumab-brain (accessed: February 2022).
[109]M. S. Kariolis, R. C. Wells, J. A. Getz, W. Kwan, C. S. Mahon, R. Tong, D. J. Kim, A. Srivastava, C. Bedard, K. R. Henne, T. Giese, V. A. Assimon, X. Chen, Y. Zhang, H. Solanoy, K. Jenkins, P. E. Sanchez, L. Kane, T. Miyamoto, K. S. Chew, M. E. Pizzo, N. Liang, M. E. K. Calvert, S. L. DeVos, S. Baskaran, S. Hall, Z. K. Sweeney, R. G. Thorne, R. J.Watts, M. S. Dennis, A. P. Silverman, Y. J. Y. Zuchero, Sci. Transl. Med. 2020, 12, 545. 32461332

Sorted by citations

Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease
Thawabteh, A. M., Ghanem, A. W., AbuMadi, S., Thaher, D., Jaghama, W., Karaman, D., & Karaman, R. (2024) · Molecules · doi:10.3390/molecules29215131 · Cited by 56 · see citing works
“It involves administering multiple doses of the whole A β 1–6 peptide linked to the ADP-Q carrier, a virus-like particle that generates high-titer anti-A β antibodies [140,141,153,154].”
Background

Authors: Parrocha, C. M. T., & Nowick, J. S.
Affiliations: University of California, Irvine (US)
Corresponding author: Nowick, James S.
ORCID: Parrocha, Chelsea Marie T.
Nowick, James S.
Venue: Peptide Science
Publisher: Wiley
Published: 2022-06-24
Volume: 115
Issue: 1
ISSN: 2475-8817 (ISSN-L)
DOI: 10.1002/pep2.24289
PMC: PMC9916509
OpenAlex: W4283379578
Cited by: 24
References: 66
Citations by year: 2026: 3 · 2025: 5 · 2024: 10 · 2023: 4 · 2022: 2
FWCI: 3.25
Type: journal article
Language: en
Update notices: erratum (2023-04-19)
Open access: hybrid
doi.org
Licence: cc-by
creativecommons.org/licenses/by/4.0/ (vor)
Locations: Peptide Science (publishedVersion, cc-by)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
eScholarship (California Digital Library) (submittedVersion, cc-by)
Funders: National Institutes of Health (AG062296)
Topics: Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords: Alzheimer's disease, peptide vaccine, immunotherapy, amyloid-beta, tau protein, monoclonal antibodies, aducanumab, clinical trials, protein aggregation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Current peptide vaccine and immunotherapy approaches against Alzheimer’s disease

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Self-check

Cites

Cited by

Related

Record

About these checks